Related Experiment Video

Updated: Jun 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chad A Reade1, Apar Kishor Ganti

  • 1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Cetuximab, an EGFR inhibitor, shows promise in non-small cell lung cancer (NSCLC) clinical trials. Further research is exploring its potential to improve outcomes for NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Chemotherapy offers limited survival benefits in non-small cell lung cancer (NSCLC).
  • The epidermal growth factor (EGF) pathway is crucial in NSCLC development and progression.
  • Targeting the EGF receptor (EGFR) pathway is a key therapeutic strategy.

Purpose of the Study:

  • To review clinical trials of cetuximab in NSCLC.
  • To identify future research directions for cetuximab in NSCLC treatment.

Main Methods:

  • Review of clinical trials involving cetuximab in NSCLC patients.
  • Analysis of preclinical data on cetuximab's efficacy.

Main Results:

  • Cetuximab, a monoclonal antibody targeting EGFR, demonstrated preclinical inhibition of NSCLC cell lines.
  • Cetuximab is under extensive clinical investigation for various NSCLC patient groups.

Conclusions:

  • Cetuximab represents a significant area of investigation for NSCLC treatment.
  • Clinical trials are essential to determine cetuximab's role in improving NSCLC patient survival and outcomes.
Keywords:
EGFRcetuximabmonoclonal antibodiesnon-small cell lung cancer

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...